Outcome of patients with advanced neoplastic disease receiving vena caval filters.

S. V. Lossef, K. H. Barth

Research output: Contribution to journalArticle

Abstract

PURPOSE: The authors examined the appropriateness and outcome of inferior vena caval (IVC) filter placements in patients with advanced malignancies and limited expected survival. PATIENTS AND METHODS: Over a 35-month period, 35 IVC filters were inserted in 34 adult patients with advanced neoplasms. Follow-up was as long as 28 months (mean, 5.2 months). Filter effectiveness, complications, recurrent pulmonary emboli, patient survival, and hospital discharge status were recorded. RESULTS: Twenty-eight patients (82%) were discharged home (n = 21) or to nursing facilities (n = 7) between 1 and 193 days (mean, 23 days) after filter insertion. Six patient (18%) died during hospitalization 1-95 days after filter insertion. The overall mean survival was 6.6 months; for patients with stage III and IV tumors mean survival was 8.0 and 5.5 months, respectively. Even among patients with stage IV disease, 59% survived longer than 3 months. There were no complications related to filter insertion and no clinical evidence of recurrent pulmonary emboli. In 14% of patients, filters enabled invasive therapeutic and palliative procedures to be performed. CONCLUSION: The presence of advanced neoplastic disease by itself should not be a deterrent to insertion of IVC filters, as most patients survived well beyond initial hospitalization.

Original languageEnglish (US)
Pages (from-to)273-277
Number of pages5
JournalJournal of Vascular and Interventional Radiology
Volume6
Issue number2
StatePublished - Mar 1995
Externally publishedYes

Fingerprint

Venae Cavae
Survival
Embolism
Hospitalization
Neoplasms
Lung
Nursing

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Outcome of patients with advanced neoplastic disease receiving vena caval filters. / Lossef, S. V.; Barth, K. H.

In: Journal of Vascular and Interventional Radiology, Vol. 6, No. 2, 03.1995, p. 273-277.

Research output: Contribution to journalArticle

@article{928bf2319e42465e8d86b95413fc5fd8,
title = "Outcome of patients with advanced neoplastic disease receiving vena caval filters.",
abstract = "PURPOSE: The authors examined the appropriateness and outcome of inferior vena caval (IVC) filter placements in patients with advanced malignancies and limited expected survival. PATIENTS AND METHODS: Over a 35-month period, 35 IVC filters were inserted in 34 adult patients with advanced neoplasms. Follow-up was as long as 28 months (mean, 5.2 months). Filter effectiveness, complications, recurrent pulmonary emboli, patient survival, and hospital discharge status were recorded. RESULTS: Twenty-eight patients (82{\%}) were discharged home (n = 21) or to nursing facilities (n = 7) between 1 and 193 days (mean, 23 days) after filter insertion. Six patient (18{\%}) died during hospitalization 1-95 days after filter insertion. The overall mean survival was 6.6 months; for patients with stage III and IV tumors mean survival was 8.0 and 5.5 months, respectively. Even among patients with stage IV disease, 59{\%} survived longer than 3 months. There were no complications related to filter insertion and no clinical evidence of recurrent pulmonary emboli. In 14{\%} of patients, filters enabled invasive therapeutic and palliative procedures to be performed. CONCLUSION: The presence of advanced neoplastic disease by itself should not be a deterrent to insertion of IVC filters, as most patients survived well beyond initial hospitalization.",
author = "Lossef, {S. V.} and Barth, {K. H.}",
year = "1995",
month = "3",
language = "English (US)",
volume = "6",
pages = "273--277",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Outcome of patients with advanced neoplastic disease receiving vena caval filters.

AU - Lossef, S. V.

AU - Barth, K. H.

PY - 1995/3

Y1 - 1995/3

N2 - PURPOSE: The authors examined the appropriateness and outcome of inferior vena caval (IVC) filter placements in patients with advanced malignancies and limited expected survival. PATIENTS AND METHODS: Over a 35-month period, 35 IVC filters were inserted in 34 adult patients with advanced neoplasms. Follow-up was as long as 28 months (mean, 5.2 months). Filter effectiveness, complications, recurrent pulmonary emboli, patient survival, and hospital discharge status were recorded. RESULTS: Twenty-eight patients (82%) were discharged home (n = 21) or to nursing facilities (n = 7) between 1 and 193 days (mean, 23 days) after filter insertion. Six patient (18%) died during hospitalization 1-95 days after filter insertion. The overall mean survival was 6.6 months; for patients with stage III and IV tumors mean survival was 8.0 and 5.5 months, respectively. Even among patients with stage IV disease, 59% survived longer than 3 months. There were no complications related to filter insertion and no clinical evidence of recurrent pulmonary emboli. In 14% of patients, filters enabled invasive therapeutic and palliative procedures to be performed. CONCLUSION: The presence of advanced neoplastic disease by itself should not be a deterrent to insertion of IVC filters, as most patients survived well beyond initial hospitalization.

AB - PURPOSE: The authors examined the appropriateness and outcome of inferior vena caval (IVC) filter placements in patients with advanced malignancies and limited expected survival. PATIENTS AND METHODS: Over a 35-month period, 35 IVC filters were inserted in 34 adult patients with advanced neoplasms. Follow-up was as long as 28 months (mean, 5.2 months). Filter effectiveness, complications, recurrent pulmonary emboli, patient survival, and hospital discharge status were recorded. RESULTS: Twenty-eight patients (82%) were discharged home (n = 21) or to nursing facilities (n = 7) between 1 and 193 days (mean, 23 days) after filter insertion. Six patient (18%) died during hospitalization 1-95 days after filter insertion. The overall mean survival was 6.6 months; for patients with stage III and IV tumors mean survival was 8.0 and 5.5 months, respectively. Even among patients with stage IV disease, 59% survived longer than 3 months. There were no complications related to filter insertion and no clinical evidence of recurrent pulmonary emboli. In 14% of patients, filters enabled invasive therapeutic and palliative procedures to be performed. CONCLUSION: The presence of advanced neoplastic disease by itself should not be a deterrent to insertion of IVC filters, as most patients survived well beyond initial hospitalization.

UR - http://www.scopus.com/inward/record.url?scp=0029263101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029263101&partnerID=8YFLogxK

M3 - Article

C2 - 7540444

AN - SCOPUS:0029263101

VL - 6

SP - 273

EP - 277

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 2

ER -